SCHEMBL1961241

SCHEMBL1961241

COc1cc(O)ccc1C=Cc1nc2ccccc2c(=O)n1-c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.66
KMT2A Q03164 9/20 0.66
MAPT P10636 6/20 0.66
TDP1 Q9NUW8 2/20 0.66
GLA P06280 1/20 0.66
PKM P14618 1/20 0.66
MCL1 Q07820 1/20 0.66
TP53 P04637 5/20 0.64
LMNA P02545 5/20 0.63
POLB P06746 4/20 0.61
KDM4E B2RXH2 1/20 0.61
ALDH1A1 P00352 1/20 0.61
BLM P54132 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
KLK7 P49862 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.58
PSMD14 O00487 1/20 0.58
GAA P10253 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1961240 1.00 MEN1 (0.66) MEN1KMT2AMAPTTDP1GLA
SCHEMBL1961083 0.89 LMNA (0.68) MEN1KMT2AMAPTTP53LMNA
SCHEMBL1961085 0.89 LMNA (0.68) MEN1KMT2AMAPTTP53LMNA
SCHEMBL1961874 0.84 TP53 (0.80) MEN1KMT2AMAPTTDP1GLA
SCHEMBL1961872 0.84 TP53 (0.80) MEN1KMT2AMAPTTDP1GLA
SCHEMBL12553526 0.84 TP53 (0.67) MEN1KMT2AMAPTTDP1GLA
SCHEMBL12581675 0.82 LMNA (0.63) MEN1KMT2AMAPTTDP1GLA
SCHEMBL3587582 0.81 LMNA (0.65) MEN1KMT2AMAPTTDP1GLA
SCHEMBL3587588 0.81 LMNA (0.65) MEN1KMT2AMAPTTDP1GLA
SCHEMBL4973403 0.81 MAPT (0.88) MEN1KMT2AMAPTTDP1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140155417-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES, INC. (US) 2014-06-05 US disclosed
US-8552009-B2 Substituted pyrimido 4.5-d pyrimidin-4-one compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. 2013-10-08 US disclosed
US-20110144135-A1 Compounds for Modulating TRPV3 Function HYDRA BIOSCIENCES, INC. (US) 2011-06-16 US disclosed
US-7893260-B2 Substituted quinazolin-4-one compounds for antagonizing TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2011-02-22 US disclosed
US-20100152209-A1 Compounds for Modulating TRPV3 Function HYDRA BIOSCIENCES INC. (US) 2010-06-17 US disclosed
EP-1954283-A2 COMPOUNDS FOR MODULATING TRPV3 FUNCTION Hydra Biosciences, Inc. (US) 2008-08-13 EP disclosed
US-20070179164-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2007-08-02 US disclosed
WO-2007056124-A2 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155417-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION TRPV3, TRPV1, TRPV4 MEN1 4683/4885KMT2A 4347/4885MAPT 1751/4885
US-20100152209-A1 Compounds for Modulating TRPV3 Function TRPV3, TRPV1, TRPV4 MEN1 4683/4885KMT2A 4347/4885MAPT 1751/4885
US-20070179164-A1 Compounds for modulating TRPV3 function TRPV3, TRPV1, TRPV4 MEN1 4683/4885KMT2A 4347/4885MAPT 1751/4885
US-20110144135-A1 Compounds for Modulating TRPV3 Function TRPV3, TRPV1, TRPV4 MEN1 4683/4885KMT2A 4347/4885MAPT 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.